Veradermics (MANE) Cash from Investing Activities (2025 - 2026)
Veradermics (MANE) posted Cash from Investing Activities of -$101.3 million for Q1 2026, down 543.17% on a QoQ basis from -$15.8 million in Q1 2025, and down 543.17% year-over-year from $22.9 million in Q1 2025.
Veradermics (MANE) Cash from Investing Activities (2025 - 2026) Analysis & Trends
Veradermics' Cash from Investing Activities history runs 2 years deep, the most recent figure standing at -$101.3 million for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Veradermics | 2.55 Bn | 2.55 Bn | - | -101.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -101.30 Mn |
| Mar 31, 2026 | -101.30 Mn |
| Mar 31, 2025 | -15.75 Mn |
| Mar 31, 2025 | -15.75 Mn |